Premium
Serial invasive imaging follow‐up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold
Author(s) -
Tovar Forero Maria Natalia,
Zandvoort Laurens,
Masdjedi Kaneshka,
Diletti Roberto,
Wilschut Jeroen,
Jaegere Peter P.,
Zijlstra Felix,
Van Mieghem Nicolas M.,
Daemen Joost
Publication year - 2020
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.28304
Subject(s) - medicine , bioresorbable scaffold , optical coherence tomography , restenosis , sirolimus , lumen (anatomy) , revascularization , scaffold , single center , stenosis , radiology , nuclear medicine , percutaneous coronary intervention , surgery , stent , biomedical engineering , myocardial infarction
Objectives To assess the performance of the commercially available Magmaris sirolimus‐eluting bioresorbable scaffold (BRS) with invasive imaging at different time points. Background Coronary BRS with a magnesium backbone have been recently studied as an alternative to polymeric scaffolds, providing enhanced vessel support and a faster resorption rate. We aimed to assess the performance of the commercially available Magmaris sirolimus‐eluting BRS at different time points. Methods A prospective, single‐center, nonrandomized study was performed at the Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands. Six patients with stable de novo coronary artery lesions underwent single‐vessel revascularization with the Magmaris sirolimus‐eluting BRS. Invasive follow‐up including intravascular imaging using optical coherence tomography (OCT) was performed at different time points. Results At a median of 8 months (range 4–12 months) target lesion failure occurred in one patient. Angiography revealed a late lumen loss of 0.59 ± 0.39 mm, a percentage diameter stenosis of 39.65 ± 15.81%, and a binary restenosis rate of 33.3%. OCT showed a significant reduction in both minimal lumen area (MLA) and scaffold area at the site of the MLA by 43.44 ± 28.62 and 38.20 ± 25.74%, respectively. A fast and heterogeneous scaffold degradation process was found with a significant reduction of patent struts at 4–5 months. Conclusions Our findings show that the latest iteration of magnesium BRS suffers from premature dismantling, resulting in a higher than expected decrease in MLA.